Relmada Therapeutics, Inc. (RLMD)

Unlocking life changing therapies

News

View all news

News - Nov 7, 2025

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

News - Nov 4, 2025

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

News - Nov 4, 2025

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Events

View all events

Event - Nov 13, 2025 4:30 PM EST

Q3 2025 Financial Results Conference Call

Read more

Company